-
A Phase 3 Randomized Double-blind Placebo- and Active-controlled Parallel-group Multicenter Protocol to Evaluate the Safety and Efficacy of Guselkumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease
Under this protocol, there are 3 separate studies: a 48-week Phase 2 dose-ranging study (ie, GALAXI 1) and 2 identical 48-week Phase 3 confirmatory studies ...Phase
Interventional
-
A Multicenter Randomized Double-Blind Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn s Disease
The purpose of this study is to assess an investigational drug called etrasimod (also referred to as the “study drug”) in the treatment of Crohn ...Phase
Interventional
